ArticleThe world journal of men's health2025
Coping with Complications that Occur after Prostate Biopsy for Satisfactory Evaluation of Call Service Using Artificial Intelligence: A Pilot Randomized Controlled Trial.
Article in The world journal of men's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeTo assess whether an artificial intelligence (AI)-based reassurance-call can inform patients about potential complications and provides reassurance following a prostate biopsy. MATERIALS AND
methodsFrom October 2022 to December 2023, 42 patients aged 40 to 70 years undergoing their first prostate biopsy were recruited. The 'Reassurance-call' service was utilized to inform and monitor patients for complications. Participants were randomized into three groups: AI-assisted Reassurance-call service (Group 1), human-assisted Reassurance-call service (Group 2), and no call (Group 3). The primary outcome measured was patient satisfaction with the Reassurance-call service, assessed using a Likert scale. Secondary outcomes included satisfaction with complication management and anxiety levels, evaluated using the Likert scale, visual analog scale (VAS), and the state-trait anxiety inventory (STAI).
resultsSatisfaction with Reassurance-call averaged 4.20 (standard deviation [SD] 0.56) for Group 1 and 4.71 (SD 0.47) for Group 2, showing a statistically significant difference. Satisfaction regarding complication management using Likert scale was 4.13 (SD 0.52) for Group 1, 4.43 (SD 0.76) for Group 2, and 3.79 (SD 0.80) for Group 3 with no statistically significant differences. Satisfaction regarding complication management using VAS averaged 8.33 (SD 1.23) for Group 1, 8.57 (SD 1.45) for Group 2, and 7.07 (SD 1.86) for Group 3, indicating significant differences. Anxiety levels using STAI averaged 40.00 (SD 10.54) for Group 1, 39.14 (SD 8.29) for Group 2, and 35.00 (SD 9.46) for Group 3, showing no significant differences. Anxiety levels using VAS averaged 5.07 (SD 2.79) for Group 1, 2.21 (SD 2.64) for Group 2, and 3.50 (SD 2.28) for Group 3, with significant differences observed.
conclusionsAI demonstrated potential in enhancing patient reassurance and managing complications post-prostate biopsy, although human interaction proved superior in certain aspects. Further studies with larger cohorts are necessary to verify the effectiveness of AI-based tools.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.